A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations (clinicaltrials.gov) - Dec 18, 2023 - P2 | N=44 | Active, not recruiting | Sponsor: Endeavor Biomedicines, Inc. | Recruiting ➔ Active, not recruiting
Enrollment closed • Metastases • Oncology • Solid Tumor • PTCH1
|